===
Medacta Group SA / Key word(s): Miscellaneous
Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024
2024-02-12 / 19:00 CET/CEST
MEDIA RELEASE
Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024
CASTEL SAN PIETRO, 12 February 2024 - Medacta Group SA ("Medacta", SIX:MOVE), a Swiss company specializing in the
design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement,
sports medicine, and spine surgeries, is pleased to announce its participation in the 2024 American Association of
Orthopaedic Surgeons (AAOS) Annual Meeting in San Francisco, CA from February 12-16, 2024, booth 1845, to learn about
GMK SpheriKA, the world's first KA-optimized femoral component indicated for total knee replacement and Medacta's
innovative offerings.
"Improving patient outcomes with innovative and sustainable solutions is our highest priority at Medacta," stated
Francesco Siccardi, Chief Executive Officer of Medacta. "As we mark our 25th anniversary, we are proud to introduce the
GMK SpheriKA, an implant and a surgical technique that is gaining a lot of attention and that could become the new gold
standard in the future of Total Knee Replacement."
Attendees will have the opportunity to learn more about GMK SpheriKA. Built upon the legacy of the GMK Sphere's
ball-in-socket design, GMK SpheriKA offers patients an implant that potentially feels more natural and stable during
daily activities, replicating the movement of the healthy knee. GMK SpheriKA is the world's first knee system
specifically designed based on the principles of Kinematic Alignment, which allows surgeons to accommodate better
optimal patella tracking in a wider range of patients.
As part of its focus on GMK SpheriKA, Medacta is also a sponsor of the AAOS 2024 OrthoDome session on Thursday,
February 12, during which surgeons will have the opportunity to view "Calipered Kinematic Alignment with the World's
First KA-Optimized Knee System." During this procedure, Stephen Howell, MD, from Lodi, CA will perform a total knee
arthroplasty on a varus knee utilizing GMK SpheriKA.
"I am excited for the opportunity to share the GMK SpheriKA technique with AAOS attendees," said Stephen Howell, MD.
"As the world's first KA-optimized knee implant, GMK SpheriKA represents a tremendous step forward in delivering
personalized patient care and returning patients to their everyday activities more quickly."
In addition, Medacta will showcase the NextAR Augmented Reality Surgical Platform, which leverages patient-specific,
unique, real-time data to complement operative workflow efficiently. Through advanced 3D planning tools, a
revolutionary and proprietary single-use tracking system, and augmented reality, NextAR enables data-driven
decision-making, allowing surgeons to perform personalized procedures based on each patient's unique anatomy and
biomechanics. NextAR is offered as a hardware system with limited capital investment and single-use instrumentation at
a low cost per case and offers the ability to host software for multiple applications. NextAR is part of the
MySolutions Personalized Ecosystem, a network of advanced digital solutions designed to improve patient outcomes and
healthcare efficiency during the entire episode of care.
All Medacta products, including GMK SpheriKA and NextAR, are supported by the comprehensive, tailored educational
offerings provided by the M.O.R.E. Institute. With an international network of expert surgeons, the M.O.R.E. Institute
is at the forefront of education with personalized, high-level educational pathways. With Medacta, the surgeon is never
alone.
Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

ABOUT MEDACTA
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic
products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland,
Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care
and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by
close collaboration with surgeon experts globally, began with minimally invasive surgical techniques and has evolved
into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a
comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in
Castel San Pietro, Switzerland, and operates in over 50 countries. Follow us on Medacta TV, YouTube, LinkedIn, and X.
RELATED TRADEMARKS
Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not
be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks.
The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks
may have foreign counterparts. GMK^® SpheriKA, NextAR^TM, MySolutions^TM Personalized Ecosystem.
Additional features:

File: Medacta to Feature GMK SpheriKA and Innovative Personalized Solutions at AAOS 2024  
End of Media Release  
Language:     English 
Company:      Medacta Group SA 

Strada Regina
6874 Castel San Pietro
Switzerland

Phone:        +41 91 696 6060 
E-mail:       info@medacta.ch 
Internet:     www.medacta.com 
ISIN:         CH0468525222 
Listed:       SIX Swiss Exchange 
EQS News ID:  1835461 

End of News EQS News Service
===
1835461 2024-02-12 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1835461&application_name=news

END) Dow Jones Newswires

February 12, 2024 13:00 ET (18:00 GMT)